Providing Pharmacoepidemiological Data Intended for Drug Regulatory Decision Making

被引：0
|
作者：
Haas, Joanna F. [1 ]
Schneeweiss, Sebastian [2 ]
Andrews, Elizabeth B. [3 ]
Bortnichak, Edward [4 ]
Jones, Judith [5 ]
机构：
[1] Genzyme Corp, Pharmacovigilance, Cambridge, MA USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] RTI Hlth Solut, Pharmacoepidemiol & Risk Management, Res Triangle Pk, NC USA
[4] Merck & Co Inc, N Wales, PA USA
[5] Degge Grp, Arlington, VA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2009年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S124 / S124
页数：1
相关论文
共 50 条
  • [41] Towards establishing criteria and best practices for analysing omic data for regulatory decision making
    Tong, Weida
    TOXICOLOGY LETTERS, 2017, 280 : S15 - S15
  • [42] Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making
    Franklin, Jessica M.
    Glynn, Robert J.
    Martin, David
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) : 867 - 877
  • [43] Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases
    Piana, Chiara
    Surh, Linda
    Furst-Recktenwald, Sabine
    Iolascon, Achille
    Jacqz-Aigrain, Evelyne M.
    Jonker, In Eke
    Russo, Roberta
    van Schalk, Ron H. N.
    Wessels, Judith
    Della Pasqua, Oscar E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 704 - 716
  • [44] Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies
    Lesko, LJ
    Atkinson, AJ
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 347 - 366
  • [45] Moving Toward a Question-Centric Approach for Regulatory Decision Making in the Context of Drug Assessment
    Musuamba, Flora T.
    Cheung, S. Y. Amy
    Colin, Pieter
    Davies, Elin H.
    Barret, Jeffrey S.
    Pappalardo, Francesco
    Chappell, Michael
    Dogne, Jean-Michel
    Ceci, Adriana
    Della Pasqua, Oscar
    Rusten, Ine S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (01) : 41 - 50
  • [46] Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan
    Nishioka, Kinue
    Makimura, Tomomi
    Ishiguro, Akihiro
    Nonaka, Takahiro
    Yamaguchi, Mitsune
    Uyama, Yoshiaki
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 35 - 43
  • [47] A Comprehensive View for Providing the Decision on Medicare Data
    Jyothi, P. Naga
    Lakshmi, D. Rajya
    Rao, K. V. S. N. Rama
    INTELLIGENT MANUFACTURING AND ENERGY SUSTAINABILITY, ICIMES 2019, 2020, 169 : 769 - 779
  • [48] Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
    Madabushi, Rajanikanth
    Seo, Paul
    Zhao, Liang
    Tegenge, Million
    Zhu, Hao
    PHARMACEUTICAL RESEARCH, 2022, 39 (08) : 1669 - 1680
  • [49] Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
    Rajanikanth Madabushi
    Paul Seo
    Liang Zhao
    Million Tegenge
    Hao Zhu
    Pharmaceutical Research, 2022, 39 : 1669 - 1680
  • [50] Pharmacogenomics and regulatory decision making:: an international perspective
    Mendrick, DL
    Brazell, C
    Mansfield, EA
    Pietrusko, R
    Barilero, I
    Hackett, J
    Stürzebecher, S
    Jacobson-Kram, D
    PHARMACOGENOMICS JOURNAL, 2006, 6 (03): : 154 - 157
12345